Skip to Main content Skip to Navigation
Journal articles

Rifabutin is bactericidal against intracellular and extracellular forms of Mycobacterium abscessus

Abstract : Mycobacterium abscessus is increasingly recognized as an emerging opportunistic pathogen causing severe lung diseases. As it is intrinsically resistant to most conventional antibiotics, there is an unmet medical need for effective treatments. Repurposing of clinically validated pharmaceuticals represents an attractive option for the development of chemotherapeutic alternatives against M. abscessus infections. In this context, rifabutin (RFB) has been shown to be active against M. abscessus and has raised renewed interest in using rifamycins for the treatment of M. abscessus pulmonary diseases. Herein, we compared the in vitro and in vivo activity of RFB against the smooth and rough variants of M. abscessus, differing in their susceptibility profile to several drugs and physiopathologial characteristics. While the activity of RFB is greater against rough strains than in smooth strains in vitro, suggesting a role of the glycopeptidolipid layer in susceptibility to RFB, both variants were equally susceptible to RFB inside human macrophages. RFB treatment also led to a reduction in the number and size of intracellular and extracelluar mycobacterial cords. Furthermore, RFB was highly effective in a zebrafish model of infection and protected the infected larvae from M. abscessus-induced killing. This was corroborated with a significant reduction in the overall bacterial burden, as well as decreased numbers of abscesses and cords, two major pathophysiological traits in infected zebrafish. This study indicates that RFB is active against M. abscessus both in vitro and in vivo, further supporting its potential usefulness as part of combination regimens targeting this difficult-to-treat mycobacterium.
Document type :
Journal articles
Complete list of metadata

Cited literature [71 references]  Display  Hide  Download

https://www.hal.inserm.fr/inserm-02971843
Contributor : Laurent Kremer Connect in order to contact the contributor
Submitted on : Monday, October 19, 2020 - 6:09:05 PM
Last modification on : Thursday, October 14, 2021 - 12:04:03 PM
Long-term archiving on: : Wednesday, January 20, 2021 - 7:24:55 PM

File

AAC00363-20R1_Merged_PDF(5).pd...
Files produced by the author(s)

Identifiers

Collections

Citation

Matt Johansen, Wassim Daher, Françoise Roquet-Banères, Clément Raynaud, Matthéo Alcaraz, et al.. Rifabutin is bactericidal against intracellular and extracellular forms of Mycobacterium abscessus. Antimicrobial Agents and Chemotherapy, American Society for Microbiology, 2020, pp.AAC.00363-20. ⟨10.1128/AAC.00363-20⟩. ⟨inserm-02971843⟩

Share

Metrics

Record views

79

Files downloads

76